Colorectal Cancer Market Predicted to See Upsurge Through 2034, Highlights DelveInsight

The Colorectal Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Colorectal Cancer pipeline products will significantly revolutionize the Colorectal Cancer market dynamics.

DelveInsight's "Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Colorectal Cancer, historical and forecasted epidemiology as well as the Colorectal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Colorectal Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Colorectal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Colorectal Cancer Market Insights
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Colorectal Cancer Market Report:
• The Colorectal Cancer market size was valued ~USD 13,000 million in 2023 and is anticipated to grow with a significant CAGR of 5% during the study period (2020-2034).
• In April 2025, Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company specializing in PLK1 inhibition for developing novel cancer therapies, announced the completion of patient enrollment in its ongoing Phase 2 CRDF-004 trial. This study is evaluating the effectiveness of onvansertib combined with standard-of-care treatment for first-line RAS-mutated metastatic colorectal cancer (mCRC).
• In February 2025, Pfizer's combination therapy for metastatic colorectal cancer (mCRC) achieved one of its main goals-enhancing progression-free survival (PFS)-in a Phase III clinical trial, reinforcing the potential for full regulatory approval. The BREAKWATER trial (NCT05217446), an open-label, active-controlled study, assessed a regimen combining Pfizer's Braftovi (encorafenib), Eli Lilly's Erbitux (cetuximab), and the chemotherapy mix mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin). The trial focused on treatment-naive mCRC patients with a BRAF V600E mutation.
• In February 2025, Averto Medical revealed that the FDA has awarded Breakthrough Device Designation to its ColoSealTM Intraluminal Colonic Diversion (ICD) System. This innovative device is designed to enhance recovery and outcomes for colorectal surgery patients by potentially eliminating the requirement for a temporary ostomy.
• In January 2025, The FDA granted approval for Amgen's KRAS G12C inhibitor, Lumakras, to be used in combination with Vectibix for the treatment of advanced colorectal cancer.
• In December 2024, EndoQuest Robotics gained FDA IDE approval for a clinical trial to evaluate its surgical robot in colorectal lesion removal. The trial will involve 50 participants across five US sites, focusing on the safety and performance of the system in ESD procedures (NCT06133387).
• In October 2024, U.S. regulators have prolonged their evaluation of Amgen's LUMAKRAS (sotorasib) for second-line colorectal cancer (CRC) by three months, delaying a possible approval decision until January 17 of next year. This extension also temporarily reduces competitive pressure on Bristol Myers Squibb's competing KRAS-inhibitor, KRAZATI (adagrasib).
• In June 2024, Bristol Myers Squibb announced US FDA accelerated approval of KRAZATI (adagrasib) in combination with cetuximab for adult patients with previously treated kras G12C-mutated locally advanced or metastatic colorectal cancer.
• In April 2024, ENHERTU was approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours, including colorectal cancer.
• Colorectal cancer is the third most frequently diagnosed cancer globally. In 2024, the United States is expected to report around 106,600 new cases of the disease. It remains the second leading cause of cancer-related deaths in the country for both men and women.
• In 2023, the United States represented approximately 30% of all newly diagnosed cases of colorectal cancer across the 7MM.
• In 2023, around 68,400 cases of colorectal cancer were reported in the United States among individuals aged 65-84 years.
• In 2023, approximately 52,000 cases of colorectal cancer were found in the right colon in the United States.
• The Surveillance, Epidemiology, and End Results (SEER) program published age and gender data for colorectal cancer patients. According to the registry, the distribution of cases by stage was as follows: 38% localized, 35% regional, 22% distant, and 4% unknown.
• Key Colorectal Cancer Companies: Plus Therapeutics, Processa Pharmaceutic als, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmace uticals Co., Ltd., G1 Therapeutics, Amgen, Mirati Therapeutics, and others
• Key Colorectal Cancer Therapies: 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR, 255, Evorpacept (ALX148), CPGJ 602 Sunshine, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras (sotorasib), MRTX849, and others
• The Colorectal Cancer epidemiology based on gender analyzed that Colorectal Cancer is more common in men as compared to women

Colorectal Cancer Overview
Colorectal cancer is a type of cancer that begins in the colon or rectm, parts of the large intestine. It typically starts as small, non-cancerous growths called polyps, which can develop into cancer over time. The exact cause of colorectal cancer is unclear, but risk factors include age, family history, certain genetic conditions, and lifestyle factors like diet, smoking, and lack of physical activity. Symptoms may include changes in bowel habits, blood in stool, abdominal pain, and unexplained weight loss. Early detection through screening, such as colonoscopy, is key to improving outcomes, as treatment options like surgery, chemotherapy, and radiation can be effective when the cancer is caught early.

Get a Free sample for the Colorectal Cancer Market Report:
https://www.delveinsight.com/report-store/colorectal-cancer-crc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Colorectal Cancer Market
The dynamics of the Colorectal Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
"According to the estimates, the highest market size of Colorectal Cancer was found in the United States, followed by Japan and the least was in Spain across the 7MM in 2021. Besides, the upcoming therapies of Colorectal Cancer are expected to combat the current unmet needs faced by the patients with Colorectal Cancer and add to the overall growth of the Colorectal Cancer market size."

Colorectal Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Colorectal Cancer Epidemiology Segmentation:
The Colorectal Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Colorectal Cancer
• Prevalent Cases of Colorectal Cancer by severity
• Gender-specific Prevalence of Colorectal Cancer
• Diagnosed Cases of Episodic and Chronic Colorectal Cancer

Download the report to understand which factors are driving Colorectal Cancer epidemiology trends @ Colorectal Cancer Epidemiological Insights
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Colorectal Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Colorectal Cancer market or expected to get launched during the study period. The analysis covers Colorectal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Colorectal Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Colorectal Cancer Therapies and Key Companies
• 188RNL-BAM: Plus Therapeutics
• PCS11T: Processa Pharmaceutic als
• HLX13: Shanghai Henlius Biotech
• Adagrasib: Mirati Therapeutics
• XL092: Exelixis
• EO2040: Enterome
• Etrumadenant: Arcus Biosciences
• LYL845: Lyell Immunopharma
• Geptanolimab: Apollomics
• HDM201: Novartis Pharmaceuticals
• TP-1454: Sumitomo Pharma Oncology
• NT219: Purple Biotech Ltd.
• NKTR-255: Nektar Therapeutics
• Evorpacept (ALX148): ALX Oncology Inc.
• CPGJ 602 Sunshine: Guojian Pharmaceutical
• Trastuzumab deruxtecan: Daiichi Sankyo
• GRT-C901: Gritstone Bio, Inc
• SHR-1701: Suzhou Suncadia Biopharmace uticals Co., Ltd.
• Trilaciclib: G1 Therapeutics
• Lumakras (sotorasib): Amgen
• MRTX849: Mirati Therapeutics

To know more about Colorectal Cancer treatment, visit @ Colorectal Cancer Medications
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Colorectal Cancer Market Strengths
• Recent advances in pathological staging and identification of the mutational status of KRAS (exon2), BRAF (V600E), and PIK3CA have greatly helped in deciding a path for anti-EGFR therapy of mCRC patients

Colorectal Cancer Market Opportunities
• The recent inclination toward the development of mutation-specific mCRC therapies has led to the approvals of KEYTRUDA, OPDIVO with or without YERVOY and BRAFTOVI in combination with ERBITUX. This clearly, opens up a window for several upcoming mutation-targeted therapies to enter and capture the market

Scope of the Colorectal Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Colorectal Cancer Companies: Plus Therapeutics, Processa Pharmaceuticals, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmace uticals Co., Ltd., G1 Therapeutics, Amgen, Mirati Therapeutics, and others
• Key Colorectal Cancer Therapies: 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR, 255, Evorpacept (ALX148), CPGJ 602 Sunshine, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras (sotorasib), MRTX849, and others
• Colorectal Cancer Therapeutic Assessment: Colorectal Cancer current marketed and Colorectal Cancer emerging therapies
• Colorectal Cancer Market Dynamics: Colorectal Cancer market drivers and Colorectal Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Colorectal Cancer Unmet Needs, KOL's views, Analyst's views, Colorectal Cancer Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.